Kamal K. E. Gadalla

Most-cited papers

1. Radically truncated MeCP2 rescues Rett syndrome-like neurological defects

   R. Tillotson, Jim Selfridge, Martha V. Koerner, Kamal K. E. Gadalla +5 more

   2017Nature144 citations Open access

   Semantic Scholar

   Save

2. Improved Survival and Reduced Phenotypic Severity Following AAV9/MECP2 Gene Transfer to Neonatal and Juvenile Male Mecp2 Knockout Mice

   Kamal K. E. Gadalla, M. Bailey, R. Spike, P. Ross +8 more

   2012Molecular Therapy137 citations Open access

   Semantic Scholar

   Save

3. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.

   Kamal K. E. Gadalla, M. Bailey, S. Cobb

   2011Biochemical Journal99 citations

   Semantic Scholar

   Save

4. Improved MECP2 Gene Therapy Extends the Survival of MeCP2-Null Mice without Apparent Toxicity after Intracisternal Delivery

   Sarah E. Sinnett, R. D. Hector, Kamal K. E. Gadalla, C. Heindel +5 more

   2017Molecular Therapy: Methods & Clinical Development68 citations Open access

   Semantic Scholar

   Save

5. Gait Analysis in a Mecp2 Knockout Mouse Model of Rett Syndrome Reveals Early-Onset and Progressive Motor Deficits

   Kamal K. E. Gadalla, P. Ross, J. Riddell, M. Bailey +1 more

   2014PLoS ONE33 citations Open access

   Semantic Scholar

   Save

6. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates

   Samantha Powers, S. Likhite, Kamal K. E. Gadalla, Carlos J. Miranda +12 more

   2023Molecular Therapy28 citations Open access

   Semantic Scholar

   Save

7. Self-regulating gene therapy ameliorates phenotypes and overcomes gene dosage sensitivity in a mouse model of Rett syndrome.

   P. Ross, Kamal K. E. Gadalla, Sophie R. Thomson, Jim Selfridge +7 more

   2025Science Translational Medicine17 citations Open access

   Semantic Scholar

   Save

8. Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome

   Stephanie A. Zlatic, D. Duong, Kamal K. E. Gadalla, Brenda Murage +14 more

   2021bioRxiv16 citations Open access

   Semantic Scholar

   Save

9. Label-free imaging of thick tissue at 1550 nm using a femtosecond optical parametric generator.

   J. Trägårdh, Gillian Robb, Kamal K. E. Gadalla, S. Cobb +3 more

   2015Optics Letters6 citations Open access

   Semantic Scholar

   Save

10. Gene therapy for Rett syndrome: prospects and challenges

    Kamal K. E. Gadalla, P. Ross, R. D. Hector, N. Bahey +2 more

    20155 citations

    Semantic Scholar

    Save

11. Reduced axonal diameter of peripheral nerve fibers in a mouse model of Rett syndrome.

    N. Bahey, Kamal K. E. Gadalla, R. McGonigal, M. Bailey +2 more

    2017Neuroscience4 citations Open access

    Semantic Scholar

    Save

12. Gene Therapy and Virus-Based Cancer Vaccines

    M. Salem, Kamal K. E. Gadalla, B. Fielding, S. Thorne

    20153 citations

    Semantic Scholar

    Save

13. 1 Radically truncated MeCP 2 rescues Rett syndrome-like neurological defects 1

    R. Tillotson, Jim Selfridge, Martha V. Koerner, Kamal K. E. Gadalla +6 more

    20171 citations

    Semantic Scholar

    Save

14. A femtosecond-pulsed tunable optical parametric generator at 1530-1790 nm for label-free third harmonic generation imaging

    J. Trägårdh, Gillian Robb, Kamal K. E. Gadalla, S. Cobb +3 more

    2015Conference on Lasers and Electro-Optics0 citations

    Semantic Scholar

    Save

15. Virus-mediated delivery of MECP2 as a potential tool for the treatment of Rett syndrome

    Kamal K. E. Gadalla

    20120 citations

    Semantic Scholar

    Save